Advanced therapeutics across cell and gene therapy face multiple challenges to achieve marketing approval and clinical success, all within the tight time and cost limits of the drug development process.
Traditional approaches rely on viral or endogenous expression systems, often truncated to fit within vector size constraints, these compete with the transcriptional landscape of the cell, particularly where multiple vectors transduce the same cell, leading to complex downstream effects.
Engineered, synthetic promoters based on SynGenSys knowledge driven computational design process, support targeting, dosing, and stability enhancements through informed design and expert curation of promoter options.
We design-in the targeting, expression strength and payload requirements of your therapy, whilst designing out the factors known to contribute to instability and long-term durability limitations.
NK cell-based immunotherapies are critical for treating cancer and immune-related diseases, but current technologies often lack the potency and specificity needed for optimal gene expression and sustained therapeutic effects.
NK.SETTM – Natural Killer Synthetic Expression Technology
Transgene expression levels vary across therapies to optimise therapeutic benefit and meet the specific needs of each disease and patient population.
SynGenSys NK.SETTM contains a library of natural killer cell targeted synthetic promoters with a broad range of activity for titratable therapeutic transgene expression.
NK.SETTM promoters are designed to achieve titratable expression of immunotherapeutic payloads (e.g. CAR, IL-15) relevant to diverse NK cell therapies, such as B-cell malignancies, HER2+ solid tumours and hepatocellular carcinoma.
NK targeted activity and minimal to no off-target expression in B-cell lymphoma and liver cells.
Our soon to be available MUSCLE.SET library of promoters, developed using SynGenSys proprietary computational selection and design tools, these promoters provide broad options for strength of expression and targeting, assessed specifically against HepG2 liver cell lines.
